A Joint Effort to Tackle Two Major Global Health Challenges
The ESA, together with leading medical societies, research organisations, and industry partners, has launched a new Working Group on Sepsis and Cancer. hemotune is proud to be a founding member of this important initiative.
Why this matters
Sepsis is a life-threatening reaction to infection. For people living with cancer, the risk is especially high. Many cancer treatments, such as chemotherapy, weaken the immune system. As a result, even small infections can quickly become dangerous and lead to sepsis.
For patients with blood cancers, sepsis is one of the most common reasons for unplanned hospital stays and intensive care admissions. Survivors of sepsis often face long-term challenges, repeated infections, treatment delays, and higher overall mortality.
As cancer treatments improve and more people survive cancer, protecting patients from sepsis must become a standard part of cancer care.
What the Working Group aims to do
• Increase awareness of sepsis
• Identify where improvements are needed in clinical practice, research, and health policy
• Promote better prevention, early detection, and faster response to sepsis in cancer care
• Support research, data generation, and advocacy to improve outcomes for people with weak or suppressed immune systems
Founding organisations
The Working Group was created by the ESA together with partners such as: The Jibraan Chaudhary Sepsis Research Foundation, Blood Cancer UK, AMR Action UK, Sepsis Research FEAT, UK Sepsis Trust, IHU SEPSIS, ESICM, and hemotune AG.
Join the initiative
The Working Group welcomes additional partners, including patient organisations, academic groups, professional societies, and industry.